Table 5 Comparing patients who had lower versus those who had higher NT-proBNP at the follow-up visit
Variables | Patients with lower FU NT-proBNP (n = 23) | Patients with higher FU NT-proBNP (n = 50) | ||||
|---|---|---|---|---|---|---|
Baseline | FU | p value | Baseline | FU | p value | |
2D-LVEF | 61.3 ± 5.8 | 62.5 ± 7.1 | 0.47 | 61.8 ± 4.7 | 59.3 ± 4.4 | 0.012 |
Mean delta 2D-LVEF | 1.2 ± 7.7 | − 2.5 ± 6.9 | ||||
3D-LVEF | 60.6 ± 5.6 | 60.3 ± 6.7 | 0.87 | 62.4 ± 5.8 | 59.0 ± 6.4 | 0.01 |
Mean delta 3D-LVEF | − 0.3 ± 8.3 | − 2.7 ± 6.9 | ||||
2D LV-GLS | − 21.0 ± 1.9 | − 20.1 ± 1.7 | 0.055 | − 21.7 ± 2.4 | − 19.4 ± 2.2 | <0.001 |
Mean delta 2D LV-GLS | − 0.3 ± 0.6 | − 2.3 ± 1.8 | ||||
Median NT-proBNP, (range), pg/ml | 37.5 (66.0) | 32.1 (62.9) | <0.001 | 23.7 (446.2) | 91.5 (949.5) | <0.001 |
Median NT-proBNP change (range), pg/ml | − 5.5 (15.6) | 46.1 (515.4) | ||||